Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Antibody to human immunodeficiency virus type 1 (HIV) gp160 in mucosal specimens of asymtomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 111B gp 160 vaccine,

Go back to Resources

Antibody to human immunodeficiency virus type 1 (HIV) gp160 in mucosal specimens of asymtomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 111B gp 160 vaccine,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines

Go back to Resources

Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

ABO - mismatched renal transplantation (RT) in children: A report of the N Am Renal Transpl Co-op Study,

Go back to Resources

ABO - mismatched renal transplantation (RT) in children: A report of the N Am Renal Transpl Co-op Study,

Authors:

Location:

Go back to Resources

A partially grouped logrank test and modifications for sequential monitoring.

Go back to Resources

A partially grouped logrank test and modifications for sequential monitoring.

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Vinorelbine Tartrate [in the treatment of breast cancer],

Go back to Resources

Vinorelbine Tartrate [in the treatment of breast cancer],

Authors:

Secondary:

Pagination:

Go back to Resources

Varicella requiring hospitalization in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Go back to Resources

Varicella requiring hospitalization in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Authors:

Location:

Go back to Resources

Varicella in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study.

Go back to Resources

Varicella in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Validity of JVA interpretation in conjunction with RDC history & clinical examination to assess TMD,

Go back to Resources

Validity of JVA interpretation in conjunction with RDC history & clinical examination to assess TMD,

Authors:

Location:

Go back to Resources

Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,

Go back to Resources

Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,

Go back to Resources

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,

Authors:

Secondary:

Volume:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 111
  • Page 112
  • Page 113
  • Page 114
  • Current page 115
  • Page 116
  • Page 117
  • Page 118
  • Page 119
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification